Related references
Note: Only part of the references are listed.BCLC strategy for prognosis prediction and treatment recommendation: The 2022 update
Maria Reig et al.
JOURNAL OF HEPATOLOGY (2022)
A bispecific antibody targeting GPC3 and CD47 induced enhanced antitumor efficacy against dual antigen-expressing HCC
Kaixin Du et al.
MOLECULAR THERAPY (2021)
Hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS DISEASE PRIMERS (2021)
Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Hyuna Sung et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2021)
DT389-YP7, a Recombinant Immunotoxin against Glypican-3 That Inhibits Hepatocellular Cancer Cells: An In Vitro Study
Hamid Hashemi Yeganeh et al.
TOXINS (2021)
Recent development and optimization of pseudomonas aeruginosa exotoxin immunotoxins in cancer therapeutic applications
Tong Wu et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2021)
IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin
Nengzhi Pang et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2021)
A Rational Designed Novel Bispecific Antibody for the Treatment of GBM
Rui Sun et al.
BIOMEDICINES (2021)
Engineered Anti-GPC3 Immunotoxin, HN3-ABD-T20, Produces Regression in Mouse Liver Cancer Xenografts Through Prolonged Serum Retention
Bryan D. Fleming et al.
HEPATOLOGY (2020)
Peptide vaccine as an adjuvant therapy for glypican-3-positive hepatocellular carcinoma induces peptide-specific CTLs and improves long prognosis
Masatake Taniguchi et al.
CANCER SCIENCE (2020)
Chimeric Antigen Receptor-Glypican-3 T-Cell Therapy for Advanced Hepatocellular Carcinoma: Results of Phase I Trials
Donghua Shi et al.
CLINICAL CANCER RESEARCH (2020)
Development of Glypican-3 Targeting Immunotoxins for the Treatment of Liver Cancer: An Update
Bryan D. Fleming et al.
BIOMOLECULES (2020)
MRI-Based Radiomics Signature: A Potential Biomarker for Identifying Glypican 3-Positive Hepatocellular Carcinoma
Dongsheng Gu et al.
JOURNAL OF MAGNETIC RESONANCE IMAGING (2020)
32A9, a novel human antibody for designing an immunotoxin and CAR-T cells against glypican-3 in hepatocellular carcinoma
Xiaoyu Liu et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2020)
Intein-mediated cytoplasmic reconstitution of a split toxin enables selective cell ablation in mixed populations and tumor xenografts
Vedud Purde et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2020)
Combined Antitumor Effects of Sorafenib and GPC3-CAR T Cells in Mouse Models of Hepatocellular Carcinoma
Xiuqi Wu et al.
MOLECULAR THERAPY (2019)
Glypican 3-Targeted Therapy in Hepatocellular Carcinoma
Takahiro Nishida et al.
CANCERS (2019)
The Role of Glypican-3 in Regulating Wnt, YAP, and Hedgehog in Liver Cancer
Aarti Kolluri et al.
FRONTIERS IN ONCOLOGY (2019)
Updated use of TACE for hepatocellular carcinoma treatment: How and when to use it based on clinical evidence
Jean-Luc Raoul et al.
CANCER TREATMENT REVIEWS (2019)
Glypican-3-Specific Antibody Drug Conjugates Targeting Hepatocellular Carcinoma
Ying Fu et al.
HEPATOLOGY (2019)
Reduction of non-specific toxicity of immunotoxin by intein mediated reconstitution on target cells
Jing Wang et al.
INTERNATIONAL IMMUNOPHARMACOLOGY (2019)
Development of GPC3-Specific Chimeric Antigen Receptor-Engineered Natural Killer Cells for the Treatment of Hepatocellular Carcinoma
Min Yu et al.
MOLECULAR THERAPY (2018)
Molecular therapies and precision medicine for hepatocellular carcinoma
Josep M. Llovet et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Moxetumomab Pasudotox: First Global Approval
Sohita Dhillon
DRUGS (2018)
Production and quality control assessment of a GLP-grade immunotoxin, D2C7-(scdsFv)-PE38KDEL, for a phase I/II clinical trial
Vidyalakshmi Chandramohan et al.
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY (2017)
Construction of an immunotoxin, HN3-mPE24, targeting glypican-3 for liver cancer therapy
Chunguang Wang et al.
ONCOTARGET (2017)
Contribution of hepatitis B virus and hepatitis C virus to liver cancer in China north areas: Experience of the Chinese National Cancer Center
Minjie Wang et al.
INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES (2017)
An anti-glypican 3/CD3 bispecific T cell-redirecting antibody for treatment of solid tumors
Takahiro Ishiguro et al.
SCIENCE TRANSLATIONAL MEDICINE (2017)
Antibody or Antibody Fragments: Implications for Molecular Imaging and Targeted Therapy of Solid Tumors
Katerina T. Xenaki et al.
FRONTIERS IN IMMUNOLOGY (2017)
Efficient generation of bispecific IgG antibodies by split intein mediated protein trans-splicing system
Lei Han et al.
SCIENTIFIC REPORTS (2017)
A phase I study of anti-GPC3 chimeric antigen receptor modified T cells (GPC3 CAR-T) in Chinese patients with refractory or relapsed GPC3+hepatocellular carcinoma (r/r GPC3+HCC).
Bo Zhai et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
New knowledge of the mechanisms of sorafenib resistance in liver cancer
Yan-jing Zhu et al.
ACTA PHARMACOLOGICA SINICA (2017)
The future of antiviral immunotoxins
Katja Spiess et al.
JOURNAL OF LEUKOCYTE BIOLOGY (2016)
Hepatocellular carcinoma: From diagnosis to treatment
Miral Sadaria Grandhi et al.
SURGICAL ONCOLOGY-OXFORD (2016)
K Protection of the Furin Cleavage Site in Low-Toxicity Immunotoxins Based on Pseudomonas Exotoxin A
Gilad Kaplan et al.
TOXINS (2016)
GPC-3 in hepatocellular carcinoma: current perspectives
Yongle Wu et al.
JOURNAL OF HEPATOCELLULAR CARCINOMA (2016)
Phage display-based generation of novel internalizing antibody fragments for immunotoxin-based treatment of acute myeloid leukemia
Jenny Fitting et al.
MABS (2015)
Immunotoxin targeting glypican-3 regresses liver cancer via dual inhibition of Wnt signalling and protein synthesis
Wei Gao et al.
NATURE COMMUNICATIONS (2015)
Glypican 3 overexpression in primary and metastatic Wilms tumors
Maria Tretiakova et al.
VIRCHOWS ARCHIV (2015)
Discovery and Diagnostic Value of a Novel Oncofetal Protein: Glypican 3
Sean K. Wang et al.
ADVANCES IN ANATOMIC PATHOLOGY (2014)
Development and Scale-Up of a Commercial Fed Batch Refolding Process for an Anti-CD22 Two Chain Immunotoxin
Thomas Linke et al.
BIOTECHNOLOGY PROGRESS (2014)
Inactivation of Wnt Signaling by a Human Antibody That Recognizes the Heparan Sulfate Chains of Glypican-3 for Liver Cancer Therapy
Wei Gao et al.
HEPATOLOGY (2014)
An improved recombinant Fab-immunotoxin targeting CD22 expressing malignancies
Tapan K. Bera et al.
LEUKEMIA RESEARCH (2014)
The role of glypicans in Hedgehog signaling
Jorge Filmus et al.
MATRIX BIOLOGY (2014)
Therapeutically targeting glypican-3 via a conformation-specific single-domain antibody in hepatocellular carcinoma
Mingqian Feng et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2013)
Major Cancer Regressions in Mesothelioma After Treatment with an Anti-Mesothelin Immunotoxin and Immune Suppression
Raffit Hassan et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Abstract 2426: Anti-Glypican3 antibody for treatment of human liver cancer
Takahiro Ishiguro et al.
CANCER RESEARCH (2011)
A guide to taming a toxin - recombinant immunotoxins constructed from Pseudomonas exotoxin A for the treatment of cancer
John E. Weldon et al.
FEBS JOURNAL (2011)
Generation of a humanized anti-glypican 3 antibody by CDR grafting and stability optimization
Kiyotaka Nakano et al.
ANTI-CANCER DRUGS (2010)
Anti-CD22 Immunotoxin RFB4(dsFv)-PE38 (BL22) for CD22-Positive Hematologic Malignancies of Childhood: Preclinical Studies and Phase I Clinical Trial
Alan S. Wayne et al.
CLINICAL CANCER RESEARCH (2010)
Aprotease-resistant immunotoxin against CD22 with greatly increased activity against CLL and diminished animal toxicity
John E. Weldon et al.
BLOOD (2009)
Glypican-3 expression is correlated with poor prognosis in hepatocellular carcinoma
Hirofumi Shirakawa et al.
CANCER SCIENCE (2009)
Glypican 3 expression in human nonneoplastic, preneoplastic, and neoplastic tissues: A tissue microarray analysis of 4,387 tissue samples
Daniel Baumhoer et al.
AMERICAN JOURNAL OF CLINICAL PATHOLOGY (2008)
Anti-Glypican 3 Antibody as a Potential Antitumor Agent for Human Liver Cancer
Takahiro Ishiguro et al.
CANCER RESEARCH (2008)
Glypican-3 is overexpressed in lung squamous cell carcinoma, but not in adenocarcinoma
Sarit Aviel-Ronen et al.
MODERN PATHOLOGY (2008)
Sorafenib in advanced hepatocellular carcinoma
Josep M. Llovet et al.
NEW ENGLAND JOURNAL OF MEDICINE (2008)
Antibody constructs in cancer therapy - Protein engineering strategies to improve exposure in solid tumors
Robert A. Beckman et al.
CANCER (2007)
Drug penetration in solid tumours
Andrew I. Minchinton et al.
NATURE REVIEWS CANCER (2006)
Processing by proprotein convertases is required for glypican-3 modulation of cell survival, Wnt signaling, and gastrulation movements
B De Cat et al.
JOURNAL OF CELL BIOLOGY (2003)
Recent progress in biomolecular engineering
DDY Ryu et al.
BIOTECHNOLOGY PROGRESS (2000)
Share Paper
